Pfizer To Purchase NextWave For ADHD Drug
This article was originally published in The Pink Sheet Daily
Pfizer is exercising its option to buy privately held NextWave Pharmaceuticals. The acquisition, which is expected to close in the fourth quarter, will give Pfizer the recently approved ADHD drug Quillivant XR.
You may also be interested in...
Pfizer CFO Frank D’Amelio talks about the big pharma’s long-term vision and cost-reduction initiatives during the Morgan Stanley Healthcare conference. Management will continue reviewing the portfolio on an ongoing basis to see how best to maximize shareholder value, he said.
Pfizer begins the process to split off its animal health business with an IPO in an effort to save on taxes and refrain from diluting the current shareholder base.
Pfizer’s price of $11.85 billion for selling its pediatric nutritionals business to Nestle came in at the upper end of what most analysts expected. It plans to use the cash it expects to receive – nearly $9 billion – mostly for share repurchases and ‘”tuck-in” M&A.